Clinical trial
Randomized Phase II Study to Evaluate Induction Nivolumab-Ipilimumab, Followed by Nivolumab With Chemoradiotherapy Versus Chemoradiotherapy for Advanced Cervical Cancer
NCT05492123 is registered in ClinicalTrials.gov with Hospital Israelita Albert Einstein as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Randomized Phase II Study to Evaluate Induction Nivolumab-Ipilimumab, Followed by Nivolumab With Chemoradiotherapy Versus Chemoradiotherapy for Advanced Cervical Cancer
- Lead sponsor
- Hospital Israelita Albert Einstein
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- August 30, 2022
- Completion date
- March 31, 2028
- Enrollment
- 112 (estimated)
- Sites
- 14
Conditions
As the registry lists them; a condition with its own page is linked.